Adaptive Biotechnologies (Adaptive Biotechnologies) Gross Margin % : 57.16% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Adaptive Biotechnologies's Gross Profit for the three months ended in Dec. 2023 was $26.2 Mil. Adaptive Biotechnologies's Revenue for the three months ended in Dec. 2023 was $45.8 Mil. Therefore, Adaptive Biotechnologies's Gross Margin % for the quarter that ended in Dec. 2023 was 57.16%.

Warning Sign:

Adaptive Biotechnologies Corp gross margin has been in long-term decline. The average rate of decline per year is -3.1%.

The historical rank and industry rank for Adaptive Biotechnologies's Gross Margin % or its related term are showing as below:

ADPT' s Gross Margin % Range Over the Past 10 Years
Min: 55.63 Med: 68.06 Max: 77.1
Current: 55.63

During the past 7 years, the highest Gross Margin % of Adaptive Biotechnologies was 77.10%. The lowest was 55.63%. And the median was 68.06%.

ADPT's Gross Margin % is ranked worse than
53.88% of 735 companies
in the Biotechnology industry
Industry Median: 59.86 vs ADPT: 55.63

Adaptive Biotechnologies had a gross margin of 57.16% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Adaptive Biotechnologies was -3.10% per year.

Adaptive Biotechnologies Gross Margin % Historical Data

The historical data trend for Adaptive Biotechnologies's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Gross Margin % Chart

Adaptive Biotechnologies Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

73.82

77.10

68.06

68.75

55.63

Adaptive Biotechnologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															69.95	50.38	63.39	48.98	57.16

Competitive Comparison of Adaptive Biotechnologies's Gross Margin %

For the Biotechnology subindustry, Adaptive Biotechnologies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptive Biotechnologies's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's Gross Margin % falls into.

Adaptive Biotechnologies Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Adaptive Biotechnologies's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	94.7	/	170.276
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(170.276 - 75.553)	/	170.276
	=	55.63 %

Adaptive Biotechnologies's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	26.2	/	45.784
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(45.784 - 19.616)	/	45.784
	=	57.16 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Adaptive Biotechnologies (NAS:ADPT) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Adaptive Biotechnologies had a gross margin of 57.16% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Adaptive Biotechnologies Gross Margin % Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptive Biotechnologies (Adaptive Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (NAS:ADPT) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

1HM:Germany

Address

1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website

https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").

Executives

Kyle Piskel	officer: Principal Accounting Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Nitin Sood	officer: Chief Commercial Officer, MRD	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Tycho Peterson	officer: Chief Financial Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
R Mark Adams	officer: Chief Operating Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Stacy L Taylor	officer: SVP and General Counsel	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102
Leslie Trigg	director	C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112
Kevin T Conroy	director	5505 ENDEAVOR LANE, MADISON WI 53719
Robert Hershberg	director	3005 FIRST AVENUE, SEATTLE WA 98121
Peter M Neupert	director	13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Sharon Benzeno	officer: Chief Commercial Ofc Imm Med	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Harlan S Robins	officer: Chief Scientific Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Francis Lo	officer: Chief People Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michael J Pellini	director	222 DUTTON MILL RD, WILLISTOWN PA 19380
Chad M Robins	director, officer: CEO and Chairman	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102